NCT00007436Unknown3 期
A Phase 3, Open-Label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 试验地点
- 19
研究概览
简要总结
The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.
详细描述
Patients take tenofovir DF in combination with other antiretrovirals.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Have completed another study on tenofovir DF without toxicity.
- •Are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir DF treatment.
排除标准
- •Patients will not be eligible for this study if they:
- •Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir.
- •Are taking agents that affect kidney function, such as probenecid.
- •Are receiving systemic chemotherapy.
- •Are taking systemic corticosteroids.
- •Are taking experimental drugs except those that are approved by Gilead.
- •Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies.
- •Are pregnant or breast-feeding.
研究者
研究点 (19)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral TherapyHIV InfectionsNCT00352053Gilead Sciences87
已完成
4 期
Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis BChronic Hepatitis BNCT01277601Gilead Sciences751
已完成
1 期
Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese SubjectsHepatitis B, ChronicNCT01480622GlaxoSmithKline14
已完成
3 期
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected ChildrenHIV InfectionsNCT00528957Gilead Sciences97
Unknown
不适用
Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral TherapyAIDS/HIV PROBLEMNCT01844297Peking Union Medical College500